Clinical Trial Update: Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating relacorilant in combination with nab-paclitaxel in solid tumors has completed phase 1 and phase 2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Relacorilant (relacorilant)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-06